Compositions and methods for deep dermal drug delivery
Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for administering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical compositions comprising small particles of an active pharmaceutical ingredient can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active pharmaceutical ingredient.
1. A pharmaceutical composition comprising:
a therapeutically effective amount of spironolactone or a pharmaceutically acceptable salt thereof, wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 6 μm; and
a silicone selected from the group consisting of dimethicone and cyclomethicone.
2. The pharmaceutical composition of claim 1 , wherein the composition is an oil-in-water emulsion.
3. The pharmaceutical composition of claim 1 , wherein the composition comprises about 0.10% w/w to about 7.5% w/w of spironolactone or a salt thereof.
4. The pharmaceutical composition of claim 1 , wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 1 μm.
5. The pharmaceutical composition of claim 1 , wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 0.25 μm.
6. The pharmaceutical composition of claim 1 , wherein a primary particle size distribution of the spironolactone is characterized by a D50 value of less than about 2.7 μm.
7. The pharmaceutical composition of claim 1 , wherein a primary particle size distribution of the spironolactone is characterized by a D10 value of less than about 1.2 μm.
8. A method of treating acne in a subject in need thereof comprising:
topically administering to the subject a pharmaceutical composition comprising: (a) a therapeutically effective amount of spironolactone or a pharmaceutically acceptable salt thereof, wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 6 μm; and (b) a silicone selected from the group consisting of dimethicone and cyclomethicone.
9. The method of claim 8 , wherein the spironolactone is delivered to the pilosebaceous unit.
10. The method of claim 8 , wherein the spironolactone achieves dermal penetration of at least 1 mm in the subject.
11. The method of claim 8 , wherein the pharmaceutical composition is an oil-in-water emulsion.
12. The method of claim 8 , wherein the composition comprises about 0.10% w/w to about 7.5% w/w of spironolactone or a salt thereof.
13. The method of claim 8 , wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 1 μm.
14. The method of claim 8 , wherein a primary particle size distribution of the spironolactone is characterized by a D90 value of less than about 0.25 μm.
15. The method of claim 8 , wherein a primary particle size distribution of the spironolactone is characterized by a D50 value of less than about 2.7 μm.
16. The method of claim 8 , wherein a primary particle size distribution of the spironolactone is characterized by a D10 value of less than about 1.2 μm.